Alpha Cognition (NASDAQ:ACOG) Upgraded to “Moderate Buy” at Raymond James

Raymond James upgraded shares of Alpha Cognition (NASDAQ:ACOG) to a moderate buy rating in a research note released on Tuesday,Zacks.com reports.

Separately, HC Wainwright initiated coverage on shares of Alpha Cognition in a research report on Tuesday, March 18th. They issued a “buy” rating and a $20.00 price target on the stock.

Alpha Cognition Price Performance

Shares of ACOG opened at $5.31 on Tuesday. The stock has a 50 day simple moving average of $5.86. Alpha Cognition has a 12-month low of $4.66 and a 12-month high of $7.00. The firm has a market cap of $85.07 million, a PE ratio of -2.07 and a beta of 2.50.

Hedge Funds Weigh In On Alpha Cognition

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. National Bank of Canada FI acquired a new stake in Alpha Cognition during the 4th quarter worth about $69,000. Manatuck Hill Partners LLC purchased a new position in shares of Alpha Cognition in the fourth quarter worth approximately $395,000. Tudor Investment Corp ET AL acquired a new stake in shares of Alpha Cognition during the fourth quarter valued at approximately $412,000. MYDA Advisors LLC purchased a new stake in shares of Alpha Cognition in the 4th quarter valued at approximately $589,000. Finally, Bleichroeder LP acquired a new position in Alpha Cognition in the 4th quarter worth approximately $1,024,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.